Loading organizations...
Shenogen Pharma Group is a drug discovery and development company in Beijing, China, specializing in oncology and immune-inflammatory diseases. The firm leverages biotechnology to create a pipeline of innovative small molecule drugs. Its core efforts develop novel therapeutics, exemplified by clinical programs addressing hepatocellular carcinoma.
The company was co-founded in 2006 by Dr. Kun Meng and Dr. Charlie Wang in Beijing. Dr. Meng, Chairman and CEO, brought expertise in molecular biology and drug development from institutions like Harvard. Dr. Wang, Chief Science Officer, contributed over two decades of cancer research, including tenure as an Assistant Professor at Harvard Medical School. Their combined scientific vision established the firm.
Shenogen primarily serves patients battling serious conditions, such as various cancers, through targeted therapeutic interventions. The company aims to become a world-class biopharmaceutical leader, committed to discovering and developing innovative medicines. Its long-term vision is to improve patient outcomes and quality of life through advanced healthcare solutions.
Shenogen Pharma Group has raised $67.0M across 3 funding rounds.
Shenogen Pharma Group has raised $67.0M in total across 3 funding rounds.
Shenogen Pharma Group has raised $67.0M in total across 3 funding rounds.
Shenogen Pharma Group's investors include Qiming Venture Partners.
Shenogen Pharma Group is a China‑based drug discovery and development company focused on oncology and cancer immunotherapy, best known for its small‑molecule immunotherapy Icaritin and a pipeline spanning small molecules, biologics and oncolytic approaches[5][2].
High-Level Overview
Origin Story
Core Differentiators
Role in the Broader Tech / Biopharma Landscape
Quick Take & Future Outlook
Notes and limits: Company details are drawn from Shenogen’s website and industry profiles showing pipeline and clinical status[5][2]; public sources list founding year as 2006 and provide program phase details, but independent granular financials, complete leadership bios, and the most recent trial outcomes or regulatory filings should be checked on Shenogen’s corporate releases or clinical trial registries for the latest updates[3][4].
Shenogen Pharma Group has raised $67.0M across 3 funding rounds. Most recently, it raised $45.0M Series D in December 2016.
| Date | Round | Lead Investors | Other Investors |
|---|---|---|---|
| Dec 1, 2016 | $45.0M Series D | Qiming Venture Partners | |
| May 1, 2015 | $2.0M Series D | Qiming Venture Partners | |
| Aug 1, 2013 | $20.0M Series C | Qiming Venture Partners |